Literature DB >> 27225028

Immunotherapy in glioblastoma: emerging options in precision medicine.

Tiffany R Hodges1, Sherise D Ferguson1, Amy B Heimberger1.   

Abstract

Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM. With the Precision Medicine Initiative being announced in the President's State of the Union Address in 2016, GBM immunotherapy provides a useful platform for changing the landscape in treating patients with difficult disease.

Entities:  

Keywords:  glioblastoma; immunotherapy; precision medicine

Mesh：

Year:  2016        PMID： 27225028      PMCID： PMC4926530          DOI： 10.2217/cns-2016-0009

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


  115 in total

1.  Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.

Authors:  A E Sloan; R Dansey; L Zamorano; G Barger; C Hamm; F Diaz; R Baynes; G Wood
Journal:  Neurosurg Focus       Date:  2000-12-15       Impact factor: 4.047

2.  NCI-MATCH launch highlights new trial design in precision-medicine era.

Authors:  Caroline McNeil
Journal:  J Natl Cancer Inst       Date:  2015-07-03       Impact factor: 13.506

3.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

4.  Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression.

Authors:  Ling-Yuan Kong; Jun Wei; Gregory N Fuller; Brett Schrand; Konrad Gabrusiewicz; Shouhao Zhou; Ganesh Rao; George Calin; Eli Gilboa; Amy B Heimberger
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

5.  Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

Authors:  Hillary G Caruso; Lenka V Hurton; Amer Najjar; David Rushworth; Sonny Ang; Simon Olivares; Tiejuan Mi; Kirsten Switzer; Harjeet Singh; Helen Huls; Dean A Lee; Amy B Heimberger; Richard E Champlin; Laurence J N Cooper
Journal:  Cancer Res       Date:  2015-09-01       Impact factor: 12.701

6.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Authors:  Christopher E Pelloski; Karla V Ballman; Alfred F Furth; Li Zhang; E Lin; Erik P Sulman; Krishna Bhat; J Matthew McDonald; W K Alfred Yung; Howard Colman; Shiao Y Woo; Amy B Heimberger; Dima Suki; Michael D Prados; Susan M Chang; Fred G Barker; Jan C Buckner; C David James; Kenneth Aldape
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

Review 7.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

8.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

Authors:  Naoki Shinojima; Kenji Tada; Shoji Shiraishi; Takanori Kamiryo; Masato Kochi; Hideo Nakamura; Keishi Makino; Hideyuki Saya; Hirofumi Hirano; Jun-Ichi Kuratsu; Koji Oka; Yasuji Ishimaru; Yukitaka Ushio
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

9.  Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes.

Authors:  H Tsurushima; S Q Liu; K Tuboi; A Matsumura; Y Yoshii; T Nose; K Saijo; T Ohno
Journal:  Jpn J Cancer Res       Date:  1999-05

10.  Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts.

Authors:  Masasuke Ohno; Takayuki Ohkuri; Akemi Kosaka; Kuniaki Tanahashi; Carl H June; Atsushi Natsume; Hideho Okada
Journal:  J Immunother Cancer       Date:  2013-12-16       Impact factor: 13.751
View more
  6 in total

1.  Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.

Authors:  Anirudh Sattiraju; Akiva Mintz
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

2.  Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.

Authors:  Vassilis Genoud; Eliana Marinari; Sergey I Nikolaev; John C Castle; Valesca Bukur; Pierre-Yves Dietrich; Hideho Okada; Paul R Walker
Journal:  Oncoimmunology       Date:  2018-09-05       Impact factor: 8.110

3.  Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.

Authors:  Edwin Chang; Christoph Pohling; Nooshin Beygui; Chirag B Patel; Jarrett Rosenberg; Dong Ho Ha; Sanjiv S Gambhir
Journal:  J Neurooncol       Date:  2017-07-05       Impact factor: 4.130

4.  MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization.

Authors:  Landon J Hansen; Rui Yang; Kristen Roso; Wenzhe Wang; Lee Chen; Qing Yang; Christopher J Pirozzi; Yiping He
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

Review 5.  Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail.

Authors:  Zachariah P Tritz; Katayoun Ayasoufi; Aaron J Johnson
Journal:  Neurooncol Adv       Date:  2021-05-14

Review 6.  Glioblastoma Treatments: An Account of Recent Industrial Developments.

Authors:  Edouard Alphandéry
Journal:  Front Pharmacol       Date:  2018-09-13       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.